PMID- 28667816 OWN - NLM STAT- MEDLINE DCOM- 20180402 LR - 20190606 IS - 1643-3750 (Electronic) IS - 1234-1010 (Print) IS - 1234-1010 (Linking) VI - 23 DP - 2017 Jul 1 TI - Significance of Pretreatment Red Blood Cell Distribution Width in Patients with Newly Diagnosed Glioblastoma. PG - 3217-3223 AB - BACKGROUND Red blood cell distribution width (RDW) is a parameter of the complete blood count (CBC) test. Recent evidence suggests that pretreatment RDW is associated with patient survival in various malignant tumors. We explored the association of pretreatment RDW and other red blood cell (RBC) parameters with clinical parameters and assessed their prognostic impact on overall survival (OS) in patients with glioblastoma (GBM). MATERIAL AND METHODS In total, 109 patients with newly diagnosed GBM were retrospectively reviewed. The Cox proportional hazards regression model and Kaplan-Meier method were used to examine the survival function of pretreatment RDW, mean cell volume (MCV), hemoglobin (HGB), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), RBC count, and hematocrit (HCT) values in patients with newly diagnosed GBM. RESULTS Univariate analysis showed that MCV, MCHC, and RDW were associated with overall survival (OS). However, only RDW remained significant in multivariate analysis. The Kaplan-Meier survival curves showed that patients belonging to the high-RDW group had a worse median OS (293 days versus 375 days, P=0.023) than those belonging to the low-RDW group. CONCLUSIONS The present study showed that pretreatment RDW was superior to MCV and MCHC as a prognostic predictor of clinical outcome in patients newly diagnosed with GBM. Pretreatment RDW was derived directly from the CBC test, which can be easily performed in clinical practice. Therefore, pretreatment RDW values can provide additional prognostic information for patients with GBM. Further larger and prospective studies are needed to confirm these findings and to investigate the mechanism by which of RDW is associated with prognosis in patients with GBM. FAU - Liang, Ruo-Fei AU - Liang RF AD - Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China (mainland). FAU - Li, Mao AU - Li M AD - Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China (mainland). FAU - Yang, Yuan AU - Yang Y AD - Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China (mainland). FAU - Mao, Qing AU - Mao Q AD - Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China (mainland). FAU - Liu, Yan-Hui AU - Liu YH AD - Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China (mainland). LA - eng PT - Journal Article DEP - 20170701 PL - United States TA - Med Sci Monit JT - Medical science monitor : international medical journal of experimental and clinical research JID - 9609063 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Brain Neoplasms/*blood/*diagnosis MH - *Erythrocyte Indices MH - Erythrocytes/metabolism MH - Female MH - Glioblastoma/*blood/*diagnosis MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Survival Analysis MH - Young Adult PMC - PMC5505574 COIS- Conflicts of interest None. EDAT- 2017/07/02 06:00 MHDA- 2018/04/03 06:00 PMCR- 2017/07/01 CRDT- 2017/07/02 06:00 PHST- 2017/07/02 06:00 [entrez] PHST- 2017/07/02 06:00 [pubmed] PHST- 2018/04/03 06:00 [medline] PHST- 2017/07/01 00:00 [pmc-release] AID - 905204 [pii] AID - 10.12659/msm.905204 [doi] PST - epublish SO - Med Sci Monit. 2017 Jul 1;23:3217-3223. doi: 10.12659/msm.905204.